CN115515681B - Gpr52调节剂化合物 - Google Patents

Gpr52调节剂化合物 Download PDF

Info

Publication number
CN115515681B
CN115515681B CN202180033813.9A CN202180033813A CN115515681B CN 115515681 B CN115515681 B CN 115515681B CN 202180033813 A CN202180033813 A CN 202180033813A CN 115515681 B CN115515681 B CN 115515681B
Authority
CN
China
Prior art keywords
fluoro
trifluoromethyl
pyridin
benzyl
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180033813.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN115515681A (zh
Inventor
萨拉·乔安妮·巴克内尔
史蒂芬·保罗·沃特森
迈克尔·阿里斯代尔·奥布莱恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexla Pharmaceuticals Uk Ltd
Original Assignee
Nexla Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexla Pharmaceuticals Uk Ltd filed Critical Nexla Pharmaceuticals Uk Ltd
Publication of CN115515681A publication Critical patent/CN115515681A/zh
Application granted granted Critical
Publication of CN115515681B publication Critical patent/CN115515681B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Amplifiers (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
CN202180033813.9A 2020-03-13 2021-03-15 Gpr52调节剂化合物 Active CN115515681B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2003668.7A GB202003668D0 (en) 2020-03-13 2020-03-13 GPR52 Modulator compounds
GB2003668.7 2020-03-13
PCT/GB2021/050638 WO2021181122A1 (en) 2020-03-13 2021-03-15 Gpr52 modulator compounds

Publications (2)

Publication Number Publication Date
CN115515681A CN115515681A (zh) 2022-12-23
CN115515681B true CN115515681B (zh) 2024-09-03

Family

ID=70453676

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180033813.9A Active CN115515681B (zh) 2020-03-13 2021-03-15 Gpr52调节剂化合物

Country Status (23)

Country Link
US (1) US20240254101A1 (https=)
EP (1) EP4117784B1 (https=)
JP (1) JP7492597B2 (https=)
KR (1) KR20220152296A (https=)
CN (1) CN115515681B (https=)
AU (1) AU2021235257A1 (https=)
BR (1) BR112022018287A2 (https=)
CA (1) CA3175429A1 (https=)
DK (1) DK4117784T3 (https=)
ES (1) ES2992600T3 (https=)
FI (1) FI4117784T3 (https=)
GB (1) GB202003668D0 (https=)
HR (1) HRP20241375T1 (https=)
HU (1) HUE068758T2 (https=)
IL (1) IL296413B2 (https=)
LT (1) LT4117784T (https=)
MX (1) MX2022011333A (https=)
PL (1) PL4117784T3 (https=)
PT (1) PT4117784T (https=)
RS (1) RS66063B1 (https=)
SI (1) SI4117784T1 (https=)
SM (1) SMT202400402T1 (https=)
WO (1) WO2021181122A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206413A (zh) 2020-04-22 2022-02-16 美商紐羅克里生物科學有限公司 Gpr52調節劑及其使用方法
EP4330232A1 (en) * 2021-04-26 2024-03-06 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
GB202113186D0 (en) 2021-09-15 2021-10-27 Heptares Therapeutics Ltd GPR52 Modulator compounds
WO2024091541A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators
JP2026508053A (ja) * 2022-10-26 2026-03-10 ニューロクライン バイオサイエンシーズ,インコーポレイテッド Gpr52モジュレーターとしての化合物および組成物
WO2024091542A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators
WO2025252061A1 (zh) * 2024-06-04 2025-12-11 海思科医药集团股份有限公司 一种gpr52激动剂及其在医药上的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108174603A (zh) * 2015-04-29 2018-06-15 阿芮纳制药有限公司 作为gpr52调节剂的用于治疗或预防其相关病症的1-杂芳基-二氢吲哚-4-甲酰胺
WO2019053090A1 (en) * 2017-09-13 2019-03-21 Novartis Ag DIPHENYL DERIVATIVES AND USES THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037797A1 (en) * 2003-10-21 2005-04-28 Pharmacia Corporation Substituted pyrazole urea compounds for the treatment of inflammation
WO2009107391A1 (ja) 2008-02-27 2009-09-03 武田薬品工業株式会社 6員芳香環含有化合物
WO2011078360A1 (ja) 2009-12-24 2011-06-30 武田薬品工業株式会社 アミド化合物
EP2530078A1 (en) 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108174603A (zh) * 2015-04-29 2018-06-15 阿芮纳制药有限公司 作为gpr52调节剂的用于治疗或预防其相关病症的1-杂芳基-二氢吲哚-4-甲酰胺
WO2019053090A1 (en) * 2017-09-13 2019-03-21 Novartis Ag DIPHENYL DERIVATIVES AND USES THEREOF

Also Published As

Publication number Publication date
JP7492597B2 (ja) 2024-05-29
EP4117784A1 (en) 2023-01-18
SMT202400402T1 (it) 2024-11-15
GB202003668D0 (en) 2020-04-29
IL296413A (en) 2022-11-01
ES2992600T3 (en) 2024-12-16
CA3175429A1 (en) 2021-09-16
AU2021235257A1 (en) 2022-10-06
SI4117784T1 (sl) 2025-03-31
LT4117784T (lt) 2024-10-25
EP4117784B1 (en) 2024-08-28
DK4117784T3 (da) 2024-10-14
CN115515681A (zh) 2022-12-23
JP2023519666A (ja) 2023-05-12
RS66063B1 (sr) 2024-11-29
IL296413B1 (en) 2025-11-01
FI4117784T3 (fi) 2024-10-10
US20240254101A1 (en) 2024-08-01
KR20220152296A (ko) 2022-11-15
MX2022011333A (es) 2022-12-08
HUE068758T2 (hu) 2025-01-28
HRP20241375T1 (hr) 2024-12-20
PL4117784T3 (pl) 2025-01-13
BR112022018287A2 (pt) 2022-11-22
WO2021181122A1 (en) 2021-09-16
PT4117784T (pt) 2024-10-07
IL296413B2 (en) 2026-03-01

Similar Documents

Publication Publication Date Title
CN115515681B (zh) Gpr52调节剂化合物
KR102928608B1 (ko) Gpr52 조절제 화합물
CN110719911A (zh) 二氮杂双环取代的咪唑并嘧啶及其用于治疗呼吸障碍的用途
EP3386993A1 (de) Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung
EP3487856A1 (de) Substituierte diazaheterobicyclische verbindungen und ihre verwendung
JP2012507512A (ja) アミロイドβのモジュレーター
JP2017095366A (ja) 新規ビアリールアミド誘導体
KR20170096599A (ko) 단백질 키나아제 저해제인 신규 2,3,5-치환된 싸이오펜 화합물
AU2017244777A1 (en) Griseofulvin compound
TW202019923A (zh) 作為Rho-激酶抑制劑之酪胺酸醯胺衍生物
CN117999258A (zh) Gpr52调节剂化合物
JP2017535573A (ja) 置換されたピリドベンゾジアゼピノン誘導体およびそれの使用
JP7761635B2 (ja) Gpr52モジュレーター化合物
RU2844473C1 (ru) Соединения модуляторы gpr52
CA3180661A1 (en) Cycloalkyl pyrimidines as ferroportin inhibitors
HK40078521A (en) Gpr52 modulator compounds
HK40078521B (en) Gpr52 modulator compounds
HK40085266B (zh) 二氮杂双环取代的咪唑并嘧啶及其用於治疗呼吸障碍的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: Britain

Address after: Cambridge, County of Cambridge, UK

Applicant after: Nexla Pharmaceuticals UK Ltd.

Address before: Cambridge, County of Cambridge, UK

Applicant before: Heptares Therapeutics Ltd.

Country or region before: Britain

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant